ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative23.36 M27.86 M24.23 M50.97 M26.75 M129.81 MRicerca e sviluppo18.14 M20.1 M20.08 M22.35 M23.31 M85.84 MReddito operativo45.14 M37.29 M42.18 M25.32 M35.61 M140.4 MProventi non operativi, Totale-1.18 M-6.43 M-2.85 M-3.81 M-3.69 M-16.78 MOneri finanziari, al netto degli interessi capitalizzati6.42 M6.29 M6.28 M6.28 M6.63 M25.48 MProventi non operativi, esclusi gli oneri finanziari-10.56 M-10.48 M-10.64 M-10.32 M-10.84 M-42.28 MEntrate/uscite straordinarie2.95 M-2.23 M1.51 M231 K515 K23 KUtile al lordo delle imposte43.96 M30.86 M39.34 M21.51 M31.91 M123.62 MQuota di utile0-573 K000—Imposte6 M5.58 M8.3 M4.16 M7.49 M25.53 MInteressi di minoranza——————Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate37.96 M25.29 M31.03 M17.35 M24.43 M98.09 MAttività cessate——————Utile netto37.96 M25.29 M31.03 M17.35 M24.43 M98.09 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari37.96 M25.29 M31.03 M17.35 M24.43 M98.09 MUtile base per azione (EPS base)0.790.530.660.380.532.1Utile diluito per azione (EPS diluito)0.740.510.640.370.512.03Numero medio di azioni ordinarie in circolazione48.43 M47.64 M46.95 M46.47 M46.74 M187.81 MAzioni diluite in circolazione52.06 M49.89 M48.13 M47.68 M48.22 M193.91 MEBITDA77.12 M50.9 M56.8 M39.45 M68.72 M215.88 MEBIT45.14 M37.29 M42.18 M25.32 M35.61 M140.4 MCosto del fatturato99.88 M85.28 M87.92 M93.19 M97.44 M363.83 MAltri costi del venduto3.9 M200 K2.7 M1.3 M1.8 M6 MAmmortamento e svalutazione (liquidità)31.98 M13.61 M14.62 M14.13 M33.12 M75.47 M
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.